26th Annual Cancer Progress Conference  
March 17-18, 2015  
New York

Tuesday, March 17, 2015

7:00 – 8:00am  
Registration and Continental Breakfast

8:00 – 8:15am  
Opening Remarks  
Jeff Bockman, PhD, VP, Defined Health

8:15 – 9:15am  
Plenary Keynote: Progress, at What Price?  
Moderator:  
• Ed Saltzman, President, Defined Health

Panelists:  
• Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center  
• Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna  
• Lee Newcomer, MD, MHA, SVP, Oncology, Genetics and Women’s Health, United Healthcare  
• Leonard Saltz, MD, Professor of Medicine, Weill Cornell Medical College; Chief, Gastrointestinal Oncology Service, Chair, Pharmacy and Therapeutics Committee, Memorial Sloan Kettering Cancer Center

9:15 – 10:30am  
A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes  
Moderator:  
• Otis Webb Brawley, MD, FACP, Chief Medical and Scientific Officer, Executive Vice President, Research, American Cancer Society

Panelists:  
• Brad Gray, President & CEO, NanoString Technologies  
• Amy Krie, MD, Medical Oncology and Hematology, Avera McKennan  
• Manfred Lehnert, MD, VP and Head, Innovation, Oncology Therapeutic Area Unit, Takeda Pharmaceuticals International  
• Brian Leyland-Jones, MB BS, PhD, VP, Molecular and Experimental Medicine, Avera McKennan  
• John J. Sninsky, PhD, Chief Scientific Officer, CareDX

10:30 – 10:45am  
Networking Break
10:45 – 12:00pm  Tumor Panel I: Rare and Pediatric Cancers
Moderator:
• Mike Rice, MS, MBA, Senior Consultant, Defined Health
Panelists:
• Peter C. Adamson, MD, Chair, Children's Oncology Group, Alan R. Cohen Endowed Chair in Pediatrics, The Children's Hospital of Philadelphia
• Meredith K. Chuk, MD, Scientific Liaison for Sarcoma, Medical Officer, FDA
• Carlos Rodriguez-Galindo, MD, Associate Professor, Department of Pediatrics, Harvard Medical School; Medical Director, Pediatric Oncology Clinical Trials, Pediatric Oncology, Dana-Farber Cancer Institute; Director, Solid Tumor Program, Pediatric Oncology, Dana-Farber Cancer Institute
• Peter Sandor, MD, MBA, Vice President, Global Marketing Oncology, Amgen
• Maoxia Zheng, PhD, Global Development Team Leader, Pediatric Oncology, Genentech

12:00 – 1:15pm  Networking Luncheon

1:15 – 2:30pm  Immunotherapy I: Targeting Checkpoint, Co-Stimulatory and Novel Immunomodulatory MOAs
Moderator:
• Jeff Bockman, PhD, VP, Defined Health
Panelists:
• Ada Braun, MD, PhD, Chief Medical Officer, Biothera
• Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
• Johanna Joyce, PhD, Member, Memorial Sloan Kettering Cancer Center
• Hy Levitsky, MD, Adjunct Professor, Oncology, Medicine and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
• Nils Lonberg, PhD, SVP, Biologics Discovery, Bristol-Myers Squibb
• Harlan Robins, PhD, Co-Founder and Chief Scientific Officer, Adaptive Biotechnologies
• Jedd Wolchok, MD, PhD, Ludwig Center at Memorial Sloan Kettering Cancer Center

2:30 – 3:45pm  Immunotherapy II: Engineered Cell Therapy
Moderator:
• Mike Rice, MS, MBA, Senior Consultant, Defined Health
Panelists:
• Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Associate Attending Physician, Dept of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center
• Thomas J. Farrell, CEO, Bellicum Pharmaceuticals
• Prof. Dolores J. Schendel, PhD, Chief Scientific Officer, Medigene
• Gaurav Shah, MD, Global Clinical Program Head (CART / CTL019 Adoptive T-cell Therapies) Novartis Pharmaceuticals
• Cassian Yee, MD, Professor, Dept of Melanoma Medical Oncology, Professor, Dept of Immunology, Director, Solid Tumor Cell Therapy, MD Anderson Cancer Center

3:45 – 4:00pm  Networking Break
4:00 – 5:15pm  Tumor Panel II: B-Cell Malignancies: Recent Advances, Remaining Challenges and Promising New Approaches

Moderator:
• Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:
• Omar Abdel-Wahab, MD, Hematologist/Oncologist, Memorial Sloan Kettering Cancer Center
• Stanley R. Frankel, MD, Adjunct Associate Professor of Medicine, Division of Hematology/Oncology, Columbia University College of Physicians and Surgeons
• William Grossman, MD, PhD, Therapeutic Area Lead, Oncology-Global Pharmaceutical R&D/Global Medical Affairs, AbbVie
• Thomas J. Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, Distinguished Professor & Deputy Director, Research Operations, UC San Diego Moores Cancer Center

5:15 – 6:30pm  Combination Therapies: Challenges and Opportunities

Moderator:
• Jeff Bockman, PhD, VP, Defined Health

Panelists:
• Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
• Ivan Horak, MD, Chief Scientific/Medical Officer, Symphogen A/S
• Noemi Rosa, Novartis
• Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics

6:30 – 8:30pm  Cancer Progress 2015 Reception
Wednesday, March 18, 2015

7:00 – 8:00am  Continental Breakfast

8:00 – 8:15am  Opening Remarks

  Mike Rice, MS, MBA, Senior Consultant, Defined Health

8:15 – 9:15am  Keynote Address:
Technology and Big Data: Transforming Cancer Research and Care

  •  Lynda Chin, MD, Department Chair, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

9:15 – 10:30am  Bucket Trials and Drug Umbrellas

  Moderator:

  •  Haleh Saber, PhD, Principal Consultant, PAREXEL International

  Panelists:

  •  James H. Doroshow, MD, Deputy Director for Clinical and Translational Research, National Cancer Institute
  •  Patricia LoRusso, DO, Associate Center Director of Innovative Medicine, Smilow Cancer Center, Yale University
  •  Ellen V. Sigal, PhD, Chairperson & Founder, Friends of Cancer Research
  •  Eric Slosberg, PhD, Senior Director, Translational Medicine, Early Development, Strategy & Innovation, Novartis Oncology
  •  Marc Theoret, MD, Scientific Liaison for Melanoma, Lead Medical Officer, Melanoma/Sarcoma Group, FDA

10:30 – 10:45am  Networking Break

10:45 – 12:00pm  Moving Beyond Mutations to Key Drivers: From Sequence to Function to Decision

  Moderator:

  •  Jeremy P. Goldberg, President, JPG Healthcare LLC

  Panelists:

  •  Robert Cohen, MD, Calico Life Sciences
  •  Christoph Lengauer, PhD, MBA, Chief Scientific Officer, Blueprint Medicines
  •  Ronnie Morris, MD, President, Champions Oncology
  •  Rob Ruijtenbeek, PhD, Chief Scientific Officer, PamGene BV
  •  Jeffrey Settleman, PhD, Senior Director, Discovery Oncology, Genentech

12:00 – 1:15pm  Networking Luncheon
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Moderator:</th>
<th>Panelists:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 – 2:30pm</td>
<td>Exceptional Responders</td>
<td>Moderator:</td>
<td>Robert H. Glassman, MD, Managing Director Global Healthcare Investment Banking, Merrill Lynch</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
<td>Barbara A. Conley, MD, Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sean Ferree, PhD, Vice President, Diagnostic Development, NanoString Technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cecilia Schott, PharmD, MBA, Head Personalized Healthcare, Corporate Business Development, AstraZeneca</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>David Solit, MD, Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>2:30 – 3:45pm</td>
<td>Funding and Conducting Cancer Research: New Paths Forward</td>
<td>Moderator:</td>
<td>Mark J. Simon, Advisor, Torreya Partners LLC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
<td>Thomas O. Daniel, MD, Executive Vice President &amp; President, Global Research and Early Development, Global Research, Celgene</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Louis J. DeGennaro, PhD, President &amp; CEO, Leukemia &amp; Lymphoma Society</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kathleen A. Denis, PhD, CLP, AVP, Office of Technology Transfer, The Rockefeller University</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Louise M. Perkins, PhD, Chief Science Officer, Melanoma Research Alliance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nathan P. Sanburn, Director, Strategy and Business Development Oncology, Eli Lilly and Company</td>
</tr>
<tr>
<td>3:45 – 4:00pm</td>
<td>Networking Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 – 5:15pm</td>
<td>Evolution of Cancer: New Ways of Thinking about an Old Scourge</td>
<td>Moderator:</td>
<td>Jean-Pierre Bizzari, MD, EVP, Clinical Research &amp; Development, Celgene</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
<td>Robert A. Beckman, MD, Professor, Georgetown University; External Faculty, Center for Evolution and Cancer, University of California At San Francisco</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kapil Dhirin, MD, Managing Member, KAPital Consulting LLC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Noma S. Sarofim Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>5:15pm</td>
<td>Closing Remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30pm</td>
<td>Cancer Progress 2015 Conference Concludes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>